Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study
Thomas Rappl,1 Daryousch Parvizi,1 Herwig Friedl,2 Maria Wiedner,1 Simone May,1 Bettina Kranzelbinder,3 Paul Wurzer,1 Bengt Hellbom1,† 1Department of Plastic and Reconstructive Surgery, Medical University Graz, Graz, Austria; 2Institute of Statistics, Graz University of Technology, Graz,...
Main Authors: | Rappl T, Parvizi D, Friedl H, Wiedner M, May S, Kranzelbinder B, Wurzer P, Hellbom B |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-09-01
|
Series: | Clinical, Cosmetic and Investigational Dermatology |
Online Access: | http://www.dovepress.com/onset-and-duration-of-effect-of-incobotulinumtoxina-onabotulinumtoxina-a14454 |
Similar Items
-
Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
by: Prager W
Published: (2013-03-01) -
OnabotulinumtoxinA Injection for Glabellar Frown Lines as an Adjunctive Treatment for Depression
by: Witbooi, Inga Robyn
Published: (2018) -
AbobotulinumtoxinA (Dysport<sup>®</sup>), OnabotulinumtoxinA (Botox<sup>®</sup>), and IncobotulinumtoxinA (Xeomin<sup>®</sup>) Neurotoxin Content and Potential Implications for Duration of Response in Patients
by: Malgorzata Field, et al.
Published: (2018-12-01) -
Correction: Field, M. et al. AbobotulinumtoxinA (Dysport<sup>®</sup>), OnabotulinumtoxinA (Botox<sup>®</sup>), and IncobotulinumtoxinA (Xeomin<sup>®</sup>) Neurotoxin Content and Potential Implications for Duration of Response in Patients
by: Malgorzata Field, et al.
Published: (2019-02-01) -
Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
by: Prager W, et al.
Published: (2013-04-01)